ABSTRACT
@#【Objective】 To investigate the safety and benefit of doxorubicin loaded hydrophobic linear alkyl modified graphene oxide （DOX@GO- C18） served as vectors in transcatheter arterial chemoembolization （TACE）. 【Methods】 Doxorubicin loaded hydrophobic linear alkyl modified graphene oxide was manufactured and characterized. VX2 liver carcinoma was established in rabbits and the hepatic lesions were treated with TACE using DOX@GO- C18 which was dissolved in lipiodol. Pre- and post- CT scans were performed to evaluate the treatment response. Liver function was assessed via blood samples drawn on day 0（preoperative），1，3，7，and day 14. The animals were sacrificed on day 14 and tissue samples collected to stain for pathology（hematoxylin-eosin staining），lipiodol（oil red O staining）and DOX（fluorescent）.【Results】The dispersion of DOX@GO-C18 in lipiodol was highly stable. Pre-and post-CT scan revealed that the diameter of the VX2 lesions barely varied and enhancements were decreased after the treatment. Target lesions gained stable disease（SD）as the treatment response based on Response Evaluation Criteria in Solid Tumors 1.1（RECIST 1.1）. Histological examination revealed that DOX@GO-C18 was located within the tumor tissue along with the lipiodol. The release of DOX may contribute to the necrosis in tumor.【Conclusions】DOX@GO-C18［CC2］may proved to be a safe and effective vectors in TACE treatment for liver carcinoma.
ABSTRACT
@#【Objective】To evaluate the safety and effects of transcatheter arterial chemoembolization using Drug-eluted beads（DEB-TACE）plus apatinib in patients with hepatocellular carcinoma（HCC）.【Methods】A retrospective analysis was performed，which included 11 HCC patients treated with DEB- TACE and followed by a target therapy of apatinib（500 mg QD）in our clinical research center. Radiograph evaluation and tumor biomarker，alpha- fetoprotein（AFP）， were recorded before the procedure and during the follow-up of the first cycle after 4~8 weeks. Adverse events induced by apatinib were recorded. 【Results】 According to the response evaluation criteria in solid tumors （RECIST），modified response evaluation criteria in solid tumors （mRECIST） and European Association for the study of the liver （EASL） criteria，the objective response rate （ORR） was 36.4% ，63.6% ，72.7% respectively，and the disease control rate（DCR）was 90.7% ，72.7% ，81.8% respectively. AFP levels were 44 251.7 μg/L which significantly decreased after the procedure ，compared to 366 336 μ g/L ，the levels before the treatment. Four reversible grade III adverse events were recorded and no grade IV adverse events found in these cases. 【Conclusion】According to the short-term treatment response and safety，DEB- TACE combined with apatinib could be considered as a promising treatment for intermediate and advanced stage hepatoma.
ABSTRACT
[Objective]To investigate the safety and efficacy of phosphorylcholine oligomer grafted graphene oxide as a drug carrier for transcatheter arterial chemoembolization in the treatment of liver cancer.[Methods]Doxorubicin loaded folic acid labeled phosphorylcholine oligomer grafted graphene oxide(DOX@GO-PCn-FA)was prepared. Graphene ox-ide(GO)and DOX@GO-PCn-FA were injected intravenously via marginal ear vein in New Zealand white rabbits respec-tively to assess their safety and biodistribution for intravenous administration.Ten male New Zealand rabbits were used to establishe the VX2 liver cancer model and the tumor characteristics were confirmed by dynamic contrast enhanced CT scan.Catheter was inserted via femoral artery and advanced into hepatic lobar or segmental artery.Digital subtraction angi-ography(DSA)was performed to validate the tumor feeding vessels.DOX@GO-PCn-FA was injected through the cathe-ter to carry out selective transcatheter arterial chemoembolization(TACE). Dynamic enhanced CT scan and pathological examinations of major tissues and organs were implemented 7 days post TACE to evaluate the efficacy of embolization effect of DOX@GO-PCn-FA against liver tumor as well as the biodistribution and safety.[Results]Intravenous injection of GO resulted in significant thrombosis and pulmonary embolism whereas DOX@GO-PCn-FA of same dosage did not. DOX@GO-PCn-FA was capable of effectively diminishing the blood supply of liver tumors when applied in TACE. Pathologic exploration revealed that DOX@ GO-PCn-FA mainly deposited in the tumor,and no obvious complications were observed.[Conclusions]GO-PCn presented superior biocompatibility and exerted effective chemoembolization against liver cancer.